Humanigen Inc. (NASDAQ:HGEN) saw a downside of -2.50% to close Monday at $6.25 after subtracting -$0.16 on the day. The 5-day average trading volume is 1,687,740 shares of the company’s common stock. It has gained $6.49 in the past week. An average of 2,571,385 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,606,000.
HGEN’s 1-month performance is -9.16% or -$0.63 on its low of $5.68 reached on 10/01/21. The company’s shares have touched a 52-week low of $5.68 and high of $29.20, with the stock’s rally to the 52-week high happening on 03/29/21. YTD, HGEN has lost -64.29% or -$11.25. However, the current price is down -78.60%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Aug 12, 61 days have gone by since the last insider trading activity for Humanigen Inc. (HGEN). Chappell Dale (Chief Scientific Officer) most recently sold 57,551 shares at $17.16 per share on Aug 12. This transaction cost the insider $987,564. Chief Scientific Officer, Chappell Dale, sold 109,647 shares at a price of $17.07 on Aug 11. Then, on Jul 29, Chief Scientific Officer Chappell Dale sold 29,394 shares at a price of $17.03 per share. This transaction amounted to $500,703.
Humanigen Inc. (HGEN) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.24 for the sector.HGEN stock has a beta of -1.99. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 217.01 while the price-to-book (PB) in the most recent quarter is 8.45.
Humanigen Inc.’s quick ratio for the period ended June 29 was 2.40, with the current ratio over the same period at 2.40 meaning that HGEN stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.56, while the total debt to equity was 0.00The trailing 12-month EBITDA margin is -28268.59%. The firm’s gross profit as reported stood at $88.51 million against revenue of $0.31 million.
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected HGEN to announce -$0.86 per share in earnings in its latest quarter, but it posted -$1.2, representing a -39.50% surprise. EBITDA for the quarter stood at more than -$70.05 million. HGEN stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 78.03 million, with total debt at $24.63 million. Shareholders hold equity totaling $59.41 million
Let’s look briefly at Humanigen Inc. (HGEN) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 33.33% to suggest the stock is trending Neutral, with historical volatility in this time period at 46.30%.
The stock’s 5-day moving average is $6.24, reflecting a +2.97% or $0.18 change from its current price. HGEN is currently trading unch above its 20-day SMA, -66.16% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -61.23% and -69.30% respectively.
Stochastic %K and %D was 68.64% and 57.32% and the average true range (ATR) pointed at 0.49. The RSI (14) points at 28.12%, while the 14-day stochastic is at 59.23% with the period’s ATR at 0.62. The stock’s 9-day MACD Oscillator is pointing at 0.21 and 0.13 on the 14-day charts.
In the most recent analyst report for Humanigen Inc. (NASDAQ: HGEN), Jefferies downgraded it to a Hold rating. They previously had a Buy rating on the stock. Analysts offering their rating for HGEN stock have a consensus rating for the stock as Overweight. Currently, 1 brokerage advisors rate HGEN as a “sell,”, while 3 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 4 have offered a “buy” rating.
What is HGEN’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $6.00 and a high of $30.00, with their median price target at $17.00. Looking at these predictions, the average price target given by analysts is for Humanigen Inc. (HGEN) stock is $18.00.